|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia.
|
21396719 |
2011 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Association study of tryptophan hydroxylase 2 gene polymorphisms in bipolar disorder patients with panic disorder comorbidity.
|
21085052 |
2011 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
P2RX7 gene is associated consistently with mood disorders and predicts clinical outcome in three clinical cohorts.
|
21438144 |
2011 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Association study of TPH2 polymorphisms and bipolar disorder in the Han Chinese population.
|
25152196 |
2015 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Stimulation of 5-HT2C receptors improves cognitive deficits induced by human tryptophan hydroxylase 2 loss of function mutation.
|
24196946 |
2014 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
Unlike the results for schizophrenia and bipolar disorder, the increase in TDO2 protein in the major depression group was not associated with an increase in kynurenine concentration.
|
16448631 |
2006 |
|
Nonorganic psychosis
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Compared to the control group, the HPLC, RT-PCR, and immunohistochemistry results show significant elevation of (1) kynurenine in schizophrenia (1.9-fold, P = 0.02), and in bipolar disorder (1.8-fold, P = 0.04), primarily in the bipolar subgroup with psychosis (2.1-fold, P = 0.03); (2) TDO2 mRNA in schizophrenia (1.7-fold; P = 0.049); and (3) the immunohistochemistry values for the density of TDO2-positive white matter glial cells in schizophrenia (P = 0.01) and in major depression (P = 0.03) as well as the density and intensity of glial cells (in both gray and white matter) stained for TDO2 in bipolar disorder (P = 0.02).
|
16448631 |
2006 |
|
Nonorganic psychosis
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Compared to the control group, the HPLC, RT-PCR, and immunohistochemistry results show significant elevation of (1) kynurenine in schizophrenia (1.9-fold, P = 0.02), and in bipolar disorder (1.8-fold, P = 0.04), primarily in the bipolar subgroup with psychosis (2.1-fold, P = 0.03); (2) TDO2 mRNA in schizophrenia (1.7-fold; P = 0.049); and (3) the immunohistochemistry values for the density of TDO2-positive white matter glial cells in schizophrenia (P = 0.01) and in major depression (P = 0.03) as well as the density and intensity of glial cells (in both gray and white matter) stained for TDO2 in bipolar disorder (P = 0.02).
|
16448631 |
2006 |
|
SCHIZOPHRENIA 1 (disorder)
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder.
|
16448631 |
2006 |
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
To identify mechanism(s) that permit TNBC to express TDO2 and other proteins not expressed in the more well-differentiated ER<sup>+</sup> breast cancers, miRNA-200c was restored in TNBC cell lines.
|
30213797 |
2019 |
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Expression of tryptophan 2,3-dioxygenase (TDO2), an enzyme involved in tryptophan catabolism, has been linked with tumor survival and poor prognosis of brain and breast cancer.
|
30134247 |
2018 |
|
Malignant neoplasm of breast
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Publicly available data revealed that high <i>TDO2</i>, the gene encoding TDO, correlates with poor breast cancer clinical outcomes, including overall survival and distant metastasis-free survival, while expression of the gene encoding the more commonly studied tryptophan-catabolizing enzyme, <i>IDO1</i> did not.
|
30143553 |
2019 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our results define an NF-κB-regulated signaling axis that promotes anoikis resistance, suggest functional connections with inflammatory modulation by the kynurenine pathway, and highlight TDO2 as an attractive target for treatment of this aggressive breast cancer subtype.
|
26363006 |
2015 |
|
Gilles de la Tourette syndrome
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Many observations have led us to suggest that the genetic defect in TS may be a mutation of tryptophan oxygenase and that TS is inherited as a semidominant semirecessive trait, i.e., homozygosity for a common gene which shows some expression in the heterozygous state.
|
2063922 |
1991 |
|
Gilles de la Tourette syndrome
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
There was no evidence to support the hypothesis that genetic variation in the serotonin 5-HT1A receptor and tryptophan oxygenase genes causes susceptibility to Tourette's syndrome and chronic multiple tics.
|
7864272 |
1995 |
|
Gilles de la Tourette syndrome
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Exon and intron variants in the human tryptophan 2,3-dioxygenase gene: potential association with Tourette syndrome, substance abuse and other disorders.
|
8873217 |
1996 |
|
Gilles de la Tourette syndrome
|
0.040 |
Biomarker
|
disease |
BEFREE |
The low blood serotonin and tryptophan levels in TS are consistent with the wide range of behavioral disorders seen in TS and suggest tryptophan oxygenase as a possible candidate gene.
|
2389798 |
1990 |
|
Mental Depression
|
0.030 |
Biomarker
|
disease |
BEFREE |
Before its link to cancer immunotherapy was discovered in 2011, the search for TDO2 inhibitors was initially driven by depression therapy.
|
30526149 |
2019 |
|
Mental Depression
|
0.030 |
Biomarker
|
disease |
BEFREE |
Finally, this review is also directed toward assessing whether IDO and TDO are potential therapeutic target in depression associated with other diseases such as diabetes and/or cancer, as well as the development of potent IDO and TDO inhibitors.
|
30014175 |
2018 |
|
Mental Depression
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
A dysfunction of the tryptophan catabolites pathway, indicated by increased levels of tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase, is also involved in the development of depression.
|
28951145 |
2018 |
|
Depressive disorder
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
A dysfunction of the tryptophan catabolites pathway, indicated by increased levels of tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase, is also involved in the development of depression.
|
28951145 |
2018 |
|
Depressive disorder
|
0.030 |
Biomarker
|
disease |
BEFREE |
Finally, this review is also directed toward assessing whether IDO and TDO are potential therapeutic target in depression associated with other diseases such as diabetes and/or cancer, as well as the development of potent IDO and TDO inhibitors.
|
30014175 |
2018 |
|
Depressive disorder
|
0.030 |
Biomarker
|
disease |
BEFREE |
Before its link to cancer immunotherapy was discovered in 2011, the search for TDO2 inhibitors was initially driven by depression therapy.
|
30526149 |
2019 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our results define an NF-κB-regulated signaling axis that promotes anoikis resistance, suggest functional connections with inflammatory modulation by the kynurenine pathway, and highlight TDO2 as an attractive target for treatment of this aggressive breast cancer subtype.
|
26363006 |
2015 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Expression of tryptophan 2,3-dioxygenase (TDO2), an enzyme involved in tryptophan catabolism, has been linked with tumor survival and poor prognosis of brain and breast cancer.
|
30134247 |
2018 |